Izotropic Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - May 27, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is releasing this bulletin to alert and inform shareholders of the following message from CEO, Dr. John McGraw:

"On behalf of the Company, I would like to provide some assurance as to our progress and execution of our business plans. The Company has made significant strides in its commercialization plans to date and is making excellent progress. Up until recently, understanding the impacts of Covid-19 and how resulting disruptions would affect long term supply relationships and critical component procurement has been a challenge. We believe we have addressed the important line items associated with supply chain management and the timelines with respect to manufacturing the initial Izoview units for testing and the clinical study, all of which will be provided in a forthcoming news announcement."

ON BEHALF OF THE COMPANY

For investor relations inquiries, contact:James BerardEmail: jberard@izocorp.com^[1]Cell: 778-228-2314Toll Free: 1-833-IZOCORP ext.1

About Izotropic Corporation

Izotropic Corporation is commercializing dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers. Extensive preliminary studies have found that breast CT may be able to routinely detect small breast tumors in the 3-5 mm size range. The median size of breast cancer found using mammography is approximately 11 mm. Routine detection of 3 mm lesions would result in 1.5 year earlier detection over mammography.

The initial indication for use for breast CT as a diagnostic device has been confirmed. Forthcoming business objectives include identifying additional indications for use, development of accessories, and additional products, all aimed at making breast CT an indispensable tool for improving the outcomes of breast cancer.

Additional information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com^[2][3]

Forward-Looking Statements

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85631^[4]

References

1. ^{^} jberard@izocorp.com (www.newsfilecorp.com)
2. ^{^} izocorp.com (www.newsfilecorp.com)
3. ^{^} sedar.com (www.newsfilecorp.com)
4. ^{^} https://www.newsfilecorp.com/release/85631 (www.newsfilecorp.com)